Rare documented neurological disorder after COVID-19 vaccination


Credit: Pixabay / CC0 Public Domain

In two separate articles in Annals of Neurology, doctors in India and England report cases of a rare neurological disorder called Guillain-Barré syndrome after people were vaccinated against COVID-19.

Both reports describe an unusual variant of Guillain-Barré characterized by significant facial weakness. Seven cases were reported from a regional medical center in Kerala, India, where approximately 1.2 million people were vaccinated with the AstraZeneca COVID-19 vaccine. Four cases were reported from Nottingham, England, in an area where approximately 700,000 people received the same vaccine. The eleven cases were of people who had received this vaccine between 10 and 22 days earlier.

It was estimated that the frequency of Guillain-Barré syndrome in these areas was up to 10 times higher than expected.

“If the link is causal, it could be due to a cross-reaction immune response to the SARS-CoV-2 tip protein and components of the peripheral immune system,” the authors of the England report wrote.

The authors of both articles emphasize this should be on the lookout for this rare neurological syndrome after COVID-19 vaccine administration.

There is no evidence that COVID vaccines can trigger Guillain-Barré syndrome

More information:
Boby Varkey Maramattom et al, Guillain-Barré syndrome after the ChAdOx1 vaccine – S / nCoV ‐19, Annals of Neurology (2021). DOI: 10.1002 / ana.26143

Christopher Martin Allen et al, variant of Guillain-Barré syndrome that occurs after vaccination against SARS – CoV-2, Annals of Neurology (2021). DOI: 10.1002 / ana.26144

Citation: Rare Neurological Disorder Documented After Vaccination Against COVID-19 (2021, June 21) Retrieved June 21, 2021 at https://medicalxpress.com/news/2021-06-rare-neurological-disorder-documented- covid-.html

This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link